Techniclone borrows money to buy time as problems crowd in
This article was originally published in Clinica
Executive Summary
Financially troubled Techniclone has announced a string of further bad news. Its chairman of one month's standing has resigned, it has defaulted on a $3.3 million loan and its stock is threatened with a delisting from NASDAQ. Techniclone has borrowed money from investors to continue operations at reduced levels. In addition, a clinical trial into Oncolym, a direct tumour targeting agent, has been cancelled.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.